Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Paplomata · SciRah

Researcher profile · Semantic Scholar

E. Paplomata

Share profile

E. Paplomata — researcher profile on SciRah

h-index: 16
Works: 40
Citations: 3,256

Most-cited papers

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
R. Murthy, S. Loi, A. Okines, E. Paplomata +28 more
2019New England Journal of Medicine1,095 citations Open access
Semantic Scholar
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
E. Paplomata, R. O'Regan
2014Therapeutic Advances in Medical Oncology541 citations Open access
Semantic Scholar
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
N. Lin, V. Borges, C. Anders, R. Murthy +25 more
2020Journal of Clinical Oncology447 citations Open access
Semantic Scholar
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
M. Radovich, Guanglong Jiang, B. Hancock, C. Chitambar +29 more
2020JAMA Oncology296 citations Open access
Semantic Scholar
Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
G. Curigliano, V. Muêller, V. Borges, E. Hamilton +16 more
2021Annals of Oncology195 citations Open access
Semantic Scholar
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
N. Lin, R. Murthy, V. Abramson, C. Anders +23 more
2022JAMA Oncology184 citations Open access
Semantic Scholar
Everolimus: side effect profile and management of toxicities in breast cancer
E. Paplomata, A. Zelnak, R. O'Regan
2013Breast Cancer Research and Treatment96 citations
Semantic Scholar
Impact of tamoxifen therapy on fertility in breast cancer survivors
L. Shandley, J. Spencer, A. Fothergill, A. Mertens +3 more
2016Fertility and Sterility77 citations Open access
Semantic Scholar
P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer
Siobhan M. Donnelly, E. Paplomata, Bridgette M. Peake, Eduardo Sanabria +2 more
2013Current Medicinal Chemistry56 citations Open access
Semantic Scholar
Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1
Eduardo Sanabria-Figueroa, Siobhan M. Donnelly, K. Foy, Meghan C. Buss +5 more
2015Molecular Pharmacology46 citations Open access
Semantic Scholar
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
B. Schneider, Guanglong Jiang, T. Ballinger, F. Shen +29 more
2021Journal of Clinical Oncology36 citations
Semantic Scholar
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
E. Paplomata, R. O'Regan
2013Therapeutics and Clinical Risk Management29 citations Open access
Semantic Scholar
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies
S. Parashar, Nausheen Akhter, E. Paplomata, I. Elgendy +7 more
2023JACC CardioOncology24 citations Open access
Semantic Scholar
Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?
E. Paplomata, R. Nahta, R. O'Regan
2015Cancer23 citations
Semantic Scholar
Signet ring cell carcinoma of the ampulla of Vater with leptomeningeal metastases: a case report.
E. Paplomata, L. Wilfong
2011Journal of Clinical Oncology20 citations
Semantic Scholar
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
V. Mueller, A. Wardley, E. Paplomata, E. Hamilton +27 more
2021European Journal of Cancer19 citations Open access
Semantic Scholar
Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.
N. Davisson, Z. Bercu, S. Friend, E. Paplomata +4 more
2020Journal of Vascular and Interventional Radiology15 citations
Semantic Scholar
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
G. Curigliano, V. Mueller, V. Borges, E. Hamilton +16 more
202114 citations
Semantic Scholar
Abstract GS5-02: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158
M. Radovich, Guanglong Jiang, C. Chitambar, R. Nanda +24 more
202011 citations
Semantic Scholar
275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)
V. Mueller, E. Paplomata, E. Hamilton, A. Zelnak +16 more
20208 citations Open access
Semantic Scholar
Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases
A. Wardley, V. Mueller, E. Paplomata, L. Crouzet +16 more
2021Poster Spotlight Session Abstracts6 citations
Semantic Scholar
Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
E. Paplomata, A. Zelnak, C. Santa-Maria, Yuan Liu +6 more
2019Clinical Breast Cancer5 citations Open access
Semantic Scholar
ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer
E. Paplomata, R. Nahta
2018Expert Opinion on Biological Therapy5 citations
Semantic Scholar
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
A. Okines, E. Paplomata, T. Wahl, G. Wright +16 more
2020Journal of Clinical Oncology4 citations
Semantic Scholar
Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
R. Murthy, S. Loi, A. Okines, E. Paplomata +28 more
2020General Session Abstracts3 citations
Semantic Scholar
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].
G. Curigliano, V. Muêller, V. Borges, E. Hamilton +16 more
2022Annals of Oncology2 citations
Semantic Scholar
Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
B. Schneider, K. Miller, S. Badve, B. O'Neil +27 more
20172 citations
Semantic Scholar
Malakoplakia of the Genitourinary Tract: A Report of 3 Cases
E. Paplomata, N. Agarwala, I. Vouros, Dimitros A Balaxis +3 more
20102 citations
Semantic Scholar
Genital floor repair using polypropylene meshes :a comparative study
E. Paplomata, Dimitris Balaxis, Thanasis Pantelis, Stauros Karagonis +2 more
20071 citations
Semantic Scholar
Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative breast cancer
B. Schneider, Guanglong Jiang, T. Ballinger, F. Shen +29 more
2022Cancer Research0 citations
Semantic Scholar
Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
S. Kamaraju, A. Fowler, Chung-Yee Cheng, L. Chaudhary +13 more
2022Cancer Research0 citations
Semantic Scholar
Thank You to Reviewers 2021
A. Logan, A. Daud, A. Jemal, Ajay Dhakal +66 more
2021Cancer0 citations
Semantic Scholar
Edinburgh Research Explorer Tucatinib, Trastuzumab and Capecitabine for HER2+ Metastatic Breast Cancer
R. Murthy, S. Loi, A. Okines, E. Paplomata +25 more
20190 citations
Semantic Scholar
Breast Cancer, Including Brief Discussion of Male Breast Cancer
E. Paplomata, R. O'Regan
20180 citations
Semantic Scholar
Abstract P6-16-03: Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)
E. Paplomata, K. Gogineni, J. Meisel, C. Santa-Maria +7 more
20170 citations
Semantic Scholar
Impact of tamoxifen on fertility in breast cancer survivors
L. Shandley, J. Spencer, A. Fothergill, A. Mertens +2 more
20160 citations Open access
Semantic Scholar
Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).
Sharon T. Wilks, M. Modiano, A. Spira, C. Becerra +11 more
20160 citations
Semantic Scholar
The role of CHFR as a predictive marker of response to taxane-based preoperative chemotherapy in triple-negative breast cancer.
E. Paplomata, G. Sica, Shahrzad Ehdaivand, D. Nickleach +4 more
20140 citations
Semantic Scholar
Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer.
A. Zelnak, E. Paplomata, S. Murali, G. Vallabhaneni +4 more
20140 citations
Semantic Scholar
Structuring reconstruction surgery in pelvic organ prolapse surgery
E. Paplomata, A. Fotas, Dimitrios Balaxis, Theodoros Filindris +1 more
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. O'Regan×10
Invite
R. O'Regan — researcher profile on SciRah
A. Zelnak×9
Invite
A. Zelnak — researcher profile on SciRah
A. Okines×8
Invite
A. Okines — researcher profile on SciRah
E. Hamilton×8
Invite
E. Hamilton — researcher profile on SciRah

×8

Invite

S. Hurvitz — researcher profile on SciRah

Invite

D. Cameron — researcher profile on SciRah

Invite

I. Krop — researcher profile on SciRah

Invite

V. Borges — researcher profile on SciRah

Invite

K. Gelmon — researcher profile on SciRah

Invite

M. Pegram — researcher profile on SciRah

Invite

W. Feng — researcher profile on SciRah

Invite

V. Mueller — researcher profile on SciRah